Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy

NCT00005779 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Interleukin-12
BIOLOGICAL: HIV-1 C4-V3 Polyvalent Peptide Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)